{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T23:52:12Z","timestamp":1774223532767,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"S14","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Proc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Colorectal cancer (CRC) is the third most prevalent malignancy globally and the second leading cause of cancer-related mortality. Approximately 15%\u201330% of patients are diagnosed with metastatic CRC (mCRC), and despite increasing survival rates, mCRC remains fatal. There are notable variations in the incidence and mortality rates of CRC across European countries, which may be attributed to the differences in lifestyle patterns and variations in cancer diagnosis and management practices. Standard initial treatments for mCRC include chemotherapeutic agents and targeted therapies. This report presents the findings of a virtual meeting held from 21 January to 2 February 2025. The meeting included healthcare professionals from 10 Eastern European countries (Bosnia and Herzegovina, Bulgaria, Croatia, Hungary, Latvia, Lithuania, Montenegro, Romania, Serbia, and Slovenia). The experts shared their opinions on various topics such as the current clinical practice and existing clinical challenges in the treatment of patients with mCRC, factors influencing treatment choices, and the place of fruquintinib therapy in the management of mCRC. The discussion was facilitated using open-ended questions. The primary objective of this article was to provide an overview of the experts\u2019 opinions and experiences related to the current treatment approaches to mCRC management, with a focus on fruquintinib in Eastern Europe. The experts identified the need for molecular and genetic profiling, multidisciplinary coordination, limited availability of and access to targeted and newly approved medications, and lack of reimbursement as key challenges in managing patients with mCRC in these regions. The experts also highlighted the importance of patient education and participation in regional and international clinical trials of new therapeutics. They also noted the need for generating real-world evidence on the safety and efficacy of fruquintinib, its comparative efficacy versus other later-line therapies, its efficacy as an earlier line of therapy, and its sequencing in the current treatment practices. Furthermore, despite the lack of direct experience with fruquintinib, most experts acknowledged its potential efficacy as a later-line therapy for mCRC and considered its effectiveness to be comparable to that of other third-line treatments.<\/jats:p>","DOI":"10.1186\/s12919-026-00369-1","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T23:02:06Z","timestamp":1774220526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert opinion on treatment patterns in metastatic colorectal cancer management in Eastern Europe"],"prefix":"10.1186","volume":"20","author":[{"given":"L\u00e1szl\u00f3","family":"Torday","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alinta","family":"Hegmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biljana","family":"Kuki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edita","family":"Baltru\u0161kevi\u010dien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Sivina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Prejac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Risti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Reber\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Mila\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossitza Krasteva","family":"Ruseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u0161a","family":"Jungi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velko Todorov","family":"Minchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Roblek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Ur\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"369_CR1","unstructured":"World Health Organization. Colorectal Cancer. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/colorectal-cancer. Accessed on 19 Nov 2025."},{"key":"369_CR2","unstructured":"Joint Research Centre, \u201cECIS - European Cancer Information System,\u201d European Union. https:\/\/ecis.jrc.ec.europa.eu\/. Accessed on 19 Nov 2025."},{"issue":"7","key":"369_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s1470-2045(21)00199-6","volume":"22","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021;22(7):1002\u201313. https:\/\/doi.org\/10.1016\/s1470-2045(21)00199-6.","journal-title":"Lancet Oncol"},{"key":"369_CR4","unstructured":"Milcamps A, Alexandru A, Baldacchino S, St\u0103nic\u0103 L, O`grady T, Stepien M, et al. Uncovering inequalities: colorectal cancer screening in Europe, European Commission, Ispra, 2024, JRC137531. https:\/\/publications.jrc.ec.europa.eu\/repository\/handle\/JRC137531. Accessed on 19 Nov 2025."},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.01.007","volume":"165","author":"C Santucci","year":"2022","unstructured":"Santucci C, Patel L, Malvezzi M, Wojtyla C, La Vecchia C, Negri E, et al. Persisting cancer mortality gap between western and eastern Europe. Eur J Cancer. 2022;165:1\u201312. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.007.","journal-title":"Eur J Cancer"},{"issue":"9","key":"369_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s1470-2045(07)70245-0","volume":"8","author":"F Berrino","year":"2007","unstructured":"Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773\u201383. https:\/\/doi.org\/10.1016\/s1470-2045(07)70245-0.","journal-title":"Lancet Oncol"},{"issue":"1","key":"369_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"100458","DOI":"10.1016\/j.lanepe.2022.100458","volume":"21","author":"R Cardoso","year":"2022","unstructured":"Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, et al. Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: a population-based study in 9 countries. Lancet Reg Health Eur. 2022;21:100458. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100458.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"369_CR9","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.3390\/ijms24065840","volume":"24","author":"D Lavacchi","year":"2023","unstructured":"Lavacchi D, Roviello G, Guidolin A, Romano S, Venturini J, Caliman E, et al. Evaluation of fruquintinib in the continuum of care of patients with colorectal cancer. Int J Mol Sci. 2023;24(6):5840. https:\/\/doi.org\/10.3390\/ijms24065840.","journal-title":"Int J Mol Sci"},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","volume":"176","author":"N Normanno","year":"2022","unstructured":"Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.005.","journal-title":"Eur J Cancer"},{"issue":"12","key":"369_CR11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","volume":"15","author":"Q Sun","year":"2014","unstructured":"Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635\u201345. https:\/\/doi.org\/10.4161\/15384047.2014.964087.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"369_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14656566.2024.2336069","volume":"25","author":"E Stucchi","year":"2024","unstructured":"Stucchi E, Bartolini M, Airoldi M, Fazio R, Dapr\u00e0 V, Mondello G, et al. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Expert Opin Pharmacother. 2024;25(4):371\u201382. https:\/\/doi.org\/10.1080\/14656566.2024.2336069.","journal-title":"Expert Opin Pharmacother"},{"key":"369_CR13","unstructured":"FDA approves fruquintinib in refractory metastatic colorectal cancer. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer. Accessed on 19 Nov 2025."},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.2147\/dddt.s388577","volume":"18","author":"S Syaj","year":"2024","unstructured":"Syaj S, Saeed A. Profile of fruquintinib in the management of advanced refractory metastatic colorectal cancer: design, development and potential place in therapy. Drug Des Devel Ther. 2024;18:5203\u201310. https:\/\/doi.org\/10.2147\/dddt.s388577.","journal-title":"Drug Des Devel Ther"},{"key":"369_CR15","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.2147\/cmar.s215533","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787\u2013803. https:\/\/doi.org\/10.2147\/cmar.s215533.","journal-title":"Cancer Manag Res"},{"issue":"24","key":"369_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu R-H, Shen L, Xu J, Bai Y, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486\u201396. https:\/\/doi.org\/10.1001\/jama.2018.7855.","journal-title":"JAMA"},{"issue":"10395","key":"369_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(23)00772-9.","journal-title":"Lancet"},{"key":"369_CR18","doi-asserted-by":"publisher","first-page":"115641","DOI":"10.1016\/j.ejca.2025.115641","volume":"227","author":"A Dasari","year":"2025","unstructured":"Dasari A, Eng C, Lonardi S, Garcia-Carbonero R, Masuishi T, Cremolini C, et al. Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO. Eur J Cancer. 2025;227:115641. https:\/\/doi.org\/10.1016\/j.ejca.2025.115641.","journal-title":"Eur J Cancer"},{"issue":"3","key":"369_CR19","doi-asserted-by":"publisher","first-page":"oyae360","DOI":"10.1093\/oncolo\/oyae360","volume":"30","author":"C Eng","year":"2025","unstructured":"Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Oncologist. 2025;30(3):oyae360. https:\/\/doi.org\/10.1093\/oncolo\/oyae360.","journal-title":"Oncologist"},{"issue":"9","key":"369_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17460441.2025.2530597","volume":"20","author":"M San-Rom\u00e1n-Gil","year":"2025","unstructured":"San-Rom\u00e1n-Gil M, Zumstein L, Zappi A, Modrego-Sanchez A, Soldevilla B, Garcia-Carbonero R. From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy. Expert Opin Drug Discov. 2025;20(9):1099\u2013113. https:\/\/doi.org\/10.1080\/17460441.2025.2530597.","journal-title":"Expert Opin Drug Discov"},{"issue":"5","key":"369_CR21","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1200\/jop.2016.019729","volume":"13","author":"JM Jacobs","year":"2017","unstructured":"Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract. 2017;13(5):e474\u201385. https:\/\/doi.org\/10.1200\/jop.2016.019729.","journal-title":"J Oncol Pract"},{"issue":"1","key":"369_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3727\/096504022x16427607626672","volume":"29","author":"S Liu","year":"2022","unstructured":"Liu S, Lu L, Pan F, Yang C, Liang J, Liu J, et al. Real-world data: fruquintinib in treating metastatic colorectal cancer. Oncol Res. 2022;29(1):25\u201331. https:\/\/doi.org\/10.3727\/096504022x16427607626672.","journal-title":"Oncol Res"},{"issue":"4","key":"369_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.21037\/jgo-24-559","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu J, Dong M, Liu K, Lu Y, Chen K, et al. Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors. J Gastrointest Oncol. 2024;15(4):1519\u201333. https:\/\/doi.org\/10.21037\/jgo-24-559.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"369_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0384-9","volume":"10","author":"RH Xu","year":"2017","unstructured":"Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22. https:\/\/doi.org\/10.1186\/s13045-016-0384-9.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"369_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00280-016-3069-8","volume":"78","author":"J Cao","year":"2016","unstructured":"Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, et al. A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259\u201369. https:\/\/doi.org\/10.1007\/s00280-016-3069-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"369_CR26","doi-asserted-by":"publisher","unstructured":"Khan A, Khan I, Maqbool S, Ihtesham A, Khan A, Gohari P. Navigating third-line therapies: a comprehensive review of regorafenib versus fruquintinib with placebo comparator for metastatic colorectal cancer\u2014A systematic review and meta-analysis. J Clin Oncol. 2025;43(16_suppl):e15514. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e15514.","DOI":"10.1200\/JCO.2025.43.16_suppl.e15514"},{"key":"369_CR27","doi-asserted-by":"publisher","first-page":"1097911","DOI":"10.3389\/fonc.2023.1097911","volume":"13","author":"YY Deng","year":"2023","unstructured":"Deng YY, Zhang XY, Zhu PF, Lu HR, Liu Q, Pan SY, et al. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: a real-world study. Front Oncol. 2023;13:1097911. https:\/\/doi.org\/10.3389\/fonc.2023.1097911.","journal-title":"Front Oncol"},{"key":"369_CR28","doi-asserted-by":"publisher","first-page":"e15550","DOI":"10.1200\/JCO.2025.43.16_suppl.e15550","volume":"43","author":"S Qin","year":"2025","unstructured":"Qin S, Li J, Xu R, Shen L, Xu J, Bai Y, et al. Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine\/tipiracil in treating advanced metastatic colorectal cancer: a match-adjusted indirect comparison. J Clin Oncol. 2025;43:e15550. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e15550.","journal-title":"J Clin Oncol"},{"key":"369_CR29","doi-asserted-by":"publisher","first-page":"e2200233","DOI":"10.1200\/go.22.00233","volume":"8","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Battisti NML, Lawler M, Kolarova T, Daly J, Rizvi K, et al. European Cancer Organisation\u2019s inequalities network: putting cancer inequalities on the European policy map. JCO Glob Oncol. 2022;8:e2200233. https:\/\/doi.org\/10.1200\/go.22.00233.","journal-title":"JCO Glob Oncol"},{"issue":"8","key":"369_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","volume":"27","author":"N Cherny","year":"2016","unstructured":"Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European Consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27(8):1423\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdw213.","journal-title":"Ann Oncol"},{"issue":"3","key":"369_CR31","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1634\/theoncologist.2019-0523","volume":"25","author":"T Cufer","year":"2019","unstructured":"Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to novel drugs for non\u2010small cell lung cancer in central and southeastern Europe: a Central European Cooperative Oncology Group analysis. Oncologist. 2019;25(3):e598\u2013601. https:\/\/doi.org\/10.1634\/theoncologist.2019-0523.","journal-title":"Oncologist"}],"container-title":["BMC Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-026-00369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12919-026-00369-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-026-00369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T23:02:07Z","timestamp":1774220527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12919-026-00369-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":31,"journal-issue":{"issue":"S14","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1186\/s12919-026-00369-1","relation":{},"ISSN":["1753-6561"],"issn-type":[{"value":"1753-6561","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"23 March 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The meeting organised by Takeda was by invitation only. All participants accepted the invitation and attended the meeting out of free will. All participants signed an agreement before gaining access to the virtual meeting. All participants signed an authorship agreement for publication of the meeting report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Takeda organised and funded the meeting. AH, BK, EB, ES, IL, JP, LT, MR (Marija Risti\u0107), MR (Martina Reber\u0161ek), NM, RKR, SJ, and VTM received participation fees based on the time spent in the virtual meeting. TR and VU are employees of Takeda Pharmaceuticals d.o.o.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}